ARVN > first cancer pt dosed using protein degradation MOA...
It's not to same extreme degree as ASMB (with potentially 4 follow-on drugs behind the lead), but bugs me that ARVN has one direct "next generation" version of their lead drug ARV-110 in what looks like much earlier development. Why do they feel they need a next gen version of the lead drug?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.